Shiga toxin
From Proteopedia
(Difference between revisions)
| Line 27: | Line 27: | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| + | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | + | *Shiga toxin | |
| - | + | ||
| - | + | **[[1dm0]], [[1r4q]] – SdStx α+β chains – ''Shigella dysenteriae''<br /> | |
| + | **[[4m1u]] – EcStx2 α+β chains + disaccharide – ''Escherichia coli''<br /> | ||
| - | + | *Shiga-like toxin 1 | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | **[[1czw]], [[1czg]] – pHStx1 β chain (mutant) – phage H30<br /> | |
| + | **[[4ull]] – pHStx1 β chain – NMR<br /> | ||
| + | **[[1c48]] - pHStx1 β chain receptor-binding domain (mutant)<br /> | ||
| + | **[[1bos]], [[1qnu]] – pHStx1 β chain receptor-binding domain + GB3 analog<br /> | ||
| + | **[[2xsc]] – EcStx1 β chain <br /> | ||
| + | **[[1d1i]], [[1cqf]] – EcStx1 β chain (mutant) + GB3 analog <br /> | ||
| + | **[[1c4q]], [[1d1k]] – EcStx1 β chain receptor-binding domain (mutant) + GB3 analog | ||
| - | + | *Shiga-like toxin 2 | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| + | **[[2c5c]] - pHStx2 β chain + inhibitor<br /> | ||
| + | **[[1r4p]] – EcStx2 α+β chains<br /> | ||
| + | **[[3mxg]] – EcStx2 β chain (mutant)<br /> | ||
| + | **[[2bos]], [[1qoh]] – EcStx2 β chain receptor-binding domain (mutant) + GB3 analog<br /> | ||
| + | **[[2ga4]] - Stx2 α+β chains – enterobacteria phage 933W | ||
| + | }} | ||
Revision as of 10:08, 10 December 2014
| |||||||||||
3D structures of shiga toxin
Updated on 10-December-2014
References
- ↑ 1.0 1.1 Wagner PL, Livny J, Neely MN, Acheson DW, Friedman DI, Waldor MK. Bacteriophage control of Shiga toxin 1 production and release by Escherichia coli. Mol Microbiol. 2002 May;44(4):957-70. PMID:12010491
- ↑ 2.0 2.1 2.2 Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages--genomes in motion. Int J Med Microbiol. 2004 Sep;294(2-3):115-21. PMID:15493821
- ↑ Asakura H, Makino S, Kobori H, Watarai M, Shirahata T, Ikeda T, Takeshi K. Phylogenetic diversity and similarity of active sites of Shiga toxin (stx) in Shiga toxin-producing Escherichia coli (STEC) isolates from humans and animals. Epidemiol Infect. 2001 Aug;127(1):27-36. PMID:11561972
- ↑ Russell JB, Jarvis GN. Practical mechanisms for interrupting the oral-fecal lifecycle of Escherichia coli. J Mol Microbiol Biotechnol. 2001 Apr;3(2):265-72. PMID:11321582
- ↑ Nishikawa K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli. Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):239-47. Epub 2011 Jun 5. PMID:21644029 doi:10.1007/s00005-011-0130-5
- ↑ 6.0 6.1 6.2 Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol. 1994 Jan;1(1):59-64. PMID:7656009
- ↑ 7.0 7.1 Di R, Kyu E, Shete V, Saidasan H, Kahn PC, Tumer NE. Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae. Toxicon. 2011 Mar 15;57(4):525-39. Epub 2010 Dec 22. PMID:21184769 doi:10.1016/j.toxicon.2010.12.006
- ↑ Roman F, Santa A, Rimanoczky A, Toldi Z, Pataki L. [Isotope study of in vitro K(+) uptake and release of erythrocytes in juvenile diabetes with 86Rb]. Padiatr Grenzgeb. 1990;29(4):339-45. PMID:2170899

